Anabolic steroids for the treatment of weight loss in HIV-infected individuals (Q24245536)

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Effects of testosterone replacement in human immunodeficiency virus-infected women with weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

A trial of testosterone therapy for HIV-associated weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

The use of a transscrotal testosterone delivery system in the treatment of patients with weight loss related to human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Effects of testosterone administration in human immunodeficiency virus-infected women with low weight: a randomized placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Effects of androgen administration in men with the AIDS wasting syndrome. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Oxandrolone in AIDS-wasting myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Effects of testosterone and exercise on muscle leanness in eugonadal men with AIDS wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Evaluation of the effects of oxandrolone on malnourished HIV-positive pediatric patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Sustained anabolic effects of long-term androgen administration in men with AIDS wasting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Combination megestrol acetate, oxandrolone, and dietary advice restores weight in human immunodeficiency virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Testosterone replacement therapy in HIV illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Treatment of depression in HIV+men: Literature review and report of an ongoing study of testosterone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

DHEA treatment for HIV+ patients: effects on mood, androgenic and anabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Resistance exercise and oxandrolone for men with HIV-related weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Metabolic effects of nandrolone decanoate and resistance training in men with HIV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Androgen therapy improves muscle mass and strength but not muscle quality: results from two studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Effects of nandrolone decanoate therapy in borderline hypogonadal men with HIV-associated weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Monitoring changes in fat-free mass in HIV-positive men with hypotestosteronemia and AIDS wasting syndrome treated with gonadal hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Testosterone as a treatment for fatigue in HIV+ men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Can androgen therapy replete lean body mass and improve muscle function in wasting associated with human immunodeficiency virus infection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Treatments for wasting in patients with the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

AIDS wasting syndrome: trends, influence on opportunistic infections, and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Developing optimal search strategies for detecting clinically sound studies in MEDLINE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Hooked on hormones? An anabolic steroid addiction hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Changes in the incidence and predictors of wasting syndrome related to human immunodeficiency virus infection, 1987-1999.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

The five-level model: a new approach to organizing body-composition research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

7 January 2021

A comparison of megestrol acetate, nandrolone decanoate and dietary counselling for HIV associated weight loss

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

7 January 2021

Effect of anabolic steroids on HIV-related wasting myopathy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

7 January 2021

Effects of testosterone upon body composition

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

7 January 2021

Nandrolone decanoate; use in HIV-associated lipodystrophy syndrome: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

7 January 2021

Testosterone therapy for clinical symptoms of hypogonadism in eugonadal men with AIDS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

7 January 2021

Perinatal transmission--successful interventions. Where do we go from here?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

7 January 2021

Effects of testosterone and progressive resistance training in eugonadal men with AIDS wasting. A randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005483

7 January 2021